Future Trends in Robotics Should Translate to More Upside for “UBOT”

The robotics industry has proven its mettle amid the Covid-19 pandemic with machines taking the place of humans in order to stave off further infections from the virus. That said, a recent Robotics & Automation News article identified additional trends that can only further the expansion of the robotics industry–good news for ETFs like the Robotics & AI Bull 3X ETF (NYSEArca: UBOT).

“The robotics industry is one that has been evolving and growing over recent years,” the article noted. “New developments in the industry have allowed both individuals and larger corporations to perform certain tasks in a much more efficient way.”

Among the trends identified include companies teaming up, large acquisitions, scaling up inventory in retail, and reduced debates on the types of robots used for specific applications.

“This industry is set to become extremely profitable as more companies realise that they could use robots within their organisation,”

Read More
Read More

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

Genuity Science’s approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.

Under terms of the multi-year collaboration, Genuity Science will receive a combination of upfront payments and development milestones, plus product royalties.  

“Ionis’ financial strength and the success of our validated antisense technology have positioned us to invest in new technologies that enhance our R&D capabilities,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “The collaboration with Genuity Science gives us the potential to significantly increase our discovery opportunities and better understand the complexities of human diseases based on genetics.”

“We are excited to collaborate with an innovative company like Ionis,” said Rob Brainin, chief executive officer of Genuity

Read More
Read More